Mobile

An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-003815-22

An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in Patients with Prostate Cancer Requiring Androgen Ablation Therapy

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To demonstrate that the efficacy in achieving and maintaining testosterone castration levels (<=0.5 ng/mL) in prostate cancer patients treated up to either 12 or 13 months is at least 80%.

Critère d'inclusion

  • Prostate cancer

Liens